外体水凝治疗:一种革命性的方法来管理糖尿病并发症
Yiming Meng1, Jing Sun2, Yushu Ma3
1Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No. 44, Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning, China. cacamym@163.com.
Journal of nanobiotechnology
|August 12, 2025
概括
外体-水凝 (Exo-gel) 复合物通过提供再生因子,为治疗糖尿病并发症提供了一种新的方法. 这种先进的生物材料显示了神经再生,血管生成和伤口愈合的前景.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 糖尿病并发症研究研究
背景情况:
- 糖尿病并发症的传统疗法在持续的药物输送和有针对性的组织再生方面存在局限性.
- 外体-水凝 (Exo-gel) 复合物代表了一种先进的生物材料平台,将外体的治疗潜力与水凝的结构优势相结合.
研究的目的:
- 系统地审查Exosome-hydrogel (Exo-gel) 复合系统在对抗糖尿病并发症方面的变革潜力.
- 强调外凝系统的宏分子相互作用和治疗影响.
- 分析外凝系统在神经再生,血管生成和伤口愈合方面的有效性.
主要方法:
- 对外体-水凝 (Exo-gel) 复合系统的临床前证据的系统审查.
- 对外体和水凝之间的宏分子相互作用的分析.
- 在糖尿病的关键病理背景下对治疗影响的评估.
主要成果:
- 外凝系统展示了外体生物活性载荷和水凝结构性质的协同整合,以控制再生因子的传递.
- 生物聚合物和外体蛋白之间的动态相互作用增强了细胞外基质 (ECM) 重塑和生物活性稳定性.
- 临床前证据显示,exo-gel在神经再生 (施瓦恩细胞调节),血管生成恢复 (VEGF/VEGFR信号传递) 和慢性伤口愈合 (巨分化) 中具有有效性.
结论:
- 外体水凝 (Exo-gel) 技术为治疗糖尿病并发症提供了一种模式转变的方法.
- 这种先进的生物材料平台为糖尿病护理中持续的药物输送和有针对性的组织再生提供了解决方案.
- 概述了生物工程治疗系统的未来转化途径,强调了exo-gel技术的潜力.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
374
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
374
01:15Diabetes: Symptoms, Diagnosis, and Complications
692
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
692
01:20Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
01:24Glucagon-like Receptor Agonists
418
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
418
01:22Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
01:16Insulin: Dosing Regimen and Adverse Effects
259
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
259